These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 37350788)

  • 41. The Rationale for a Preventative HCV Virus-Like Particle (VLP) Vaccine.
    Torresi J
    Front Microbiol; 2017; 8():2163. PubMed ID: 29163442
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Bacterial superglue generates a full-length circumsporozoite protein virus-like particle vaccine capable of inducing high and durable antibody responses.
    Janitzek CM; Matondo S; Thrane S; Nielsen MA; Kavishe R; Mwakalinga SB; Theander TG; Salanti A; Sander AF
    Malar J; 2016 Nov; 15(1):545. PubMed ID: 27825348
    [TBL] [Abstract][Full Text] [Related]  

  • 43. An Overview of Recent Developments in the Application of Antigen Displaying Vaccine Platforms: Hints for Future SARS-CoV-2 VLP Vaccines.
    Setyo Utomo DI; Suhaimi H; Muhammad Azami NA; Azmi F; Mohd Amin MCI; Xu J
    Vaccines (Basel); 2023 Sep; 11(9):. PubMed ID: 37766182
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A tetravalent virus-like particle vaccine designed to display domain III of dengue envelope proteins induces multi-serotype neutralizing antibodies in mice and macaques which confer protection against antibody dependent enhancement in AG129 mice.
    Ramasamy V; Arora U; Shukla R; Poddar A; Shanmugam RK; White LJ; Mattocks MM; Raut R; Perween A; Tyagi P; de Silva AM; Bhaumik SK; Kaja MK; Villinger F; Ahmed R; Johnston RE; Swaminathan S; Khanna N
    PLoS Negl Trop Dis; 2018 Jan; 12(1):e0006191. PubMed ID: 29309412
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Virus-like particles in vaccine development.
    Roldão A; Mellado MC; Castilho LR; Carrondo MJ; Alves PM
    Expert Rev Vaccines; 2010 Oct; 9(10):1149-76. PubMed ID: 20923267
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Protective immunity induced by CpG ODN-adjuvanted virus-like particles containing Toxoplasma gondii proteins.
    Kang HJ; Chu KB; Kim MJ; Lee SH; Park H; Jin H; Moon EK; Quan FS
    Parasite Immunol; 2021 Jan; 43(1):e12799. PubMed ID: 33058167
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Virus-like particle (VLP) vaccine conferred complete protection against a lethal influenza virus challenge.
    Galarza JM; Latham T; Cupo A
    Viral Immunol; 2005; 18(1):244-51. PubMed ID: 15802970
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Nanoparticle and virus-like particle vaccine approaches against SARS-CoV-2.
    Kim C; Kim JD; Seo SU
    J Microbiol; 2022 Mar; 60(3):335-346. PubMed ID: 35089583
    [TBL] [Abstract][Full Text] [Related]  

  • 49.
    Shukla R; Rajpoot RK; Arora U; Poddar A; Swaminathan S; Khanna N
    Front Microbiol; 2017; 8():2644. PubMed ID: 29367852
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immunization with DNA Plasmids Coding for Crimean-Congo Hemorrhagic Fever Virus Capsid and Envelope Proteins and/or Virus-Like Particles Induces Protection and Survival in Challenged Mice.
    Hinkula J; Devignot S; Åkerström S; Karlberg H; Wattrang E; Bereczky S; Mousavi-Jazi M; Risinger C; Lindegren G; Vernersson C; Paweska J; van Vuren PJ; Blixt O; Brun A; Weber F; Mirazimi A
    J Virol; 2017 May; 91(10):. PubMed ID: 28250124
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Virus-Like Particle Systems for Vaccine Development against Viruses in the Flaviviridae Family.
    Wong SH; Jassey A; Wang JY; Wang WC; Liu CH; Lin LT
    Vaccines (Basel); 2019 Sep; 7(4):. PubMed ID: 31547131
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV.
    Liu YV; Massare MJ; Barnard DL; Kort T; Nathan M; Wang L; Smith G
    Vaccine; 2011 Sep; 29(38):6606-13. PubMed ID: 21762752
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Induction of virus-neutralizing antibodies and T cell responses by dengue virus type 1 virus-like particles prepared from Pichia pastoris.
    Tang YX; Jiang LF; Zhou JM; Yin Y; Yang XM; Liu WQ; Fang DY
    Chin Med J (Engl); 2012 Jun; 125(11):1986-92. PubMed ID: 22884066
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Structural Characterization and Formulation Development of a Trivalent Equine Encephalitis Virus-Like Particle Vaccine Candidate.
    Toprani VM; Cheng Y; Wahome N; Khasa H; Kueltzo LA; Schwartz RM; Middaugh CR; Joshi SB; Volkin DB
    J Pharm Sci; 2018 Oct; 107(10):2544-2558. PubMed ID: 29883665
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Virus-like Particles of Nodavirus Displaying the Receptor Binding Domain of SARS-CoV-2 Spike Protein: A Potential VLP-Based COVID-19 Vaccine.
    Kumar K; Tan WS; Arshad SS; Ho KL
    Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901827
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immunogenicity and performance of an enterovirus 71 virus-like-particle vaccine in nonhuman primates.
    Lim PY; Hickey AC; Jamiluddin MF; Hamid S; Kramer J; Santos R; Bossart KN; Cardosa MJ
    Vaccine; 2015 Nov; 33(44):6017-24. PubMed ID: 26271825
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Virus-like particles displaying envelope domain III of dengue virus type 2 induce virus-specific antibody response in mice.
    Arora U; Tyagi P; Swaminathan S; Khanna N
    Vaccine; 2013 Jan; 31(6):873-8. PubMed ID: 23261049
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Malaria vaccine candidates displayed on novel virus-like particles are immunogenic and induce transmission-blocking activity.
    Chan JA; Wetzel D; Reiling L; Miura K; Drew DR; Gilson PR; Anderson DA; Richards JS; Long CA; Suckow M; Jenzelewski V; Tsuboi T; Boyle MJ; Piontek M; Beeson JG
    PLoS One; 2019; 14(9):e0221733. PubMed ID: 31504038
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Flavivirus vaccines: Virus-like particles and single-round infectious particles as promising alternatives.
    Cuevas-Juárez E; Pando-Robles V; Palomares LA
    Vaccine; 2021 Nov; 39(48):6990-7000. PubMed ID: 34753613
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Virus-like particle - mediated delivery of the RIG-I agonist M8 induces a type I interferon response and protects cells against viral infection.
    Palermo E; Alexandridi M; Di Carlo D; Muscolini M; Hiscott J
    Front Cell Infect Microbiol; 2022; 12():1079926. PubMed ID: 36590581
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.